As cancer mortality is high in most regions of the world, early screening of cancer has become increasingly important. Minimally invasive screening programs that use peripheral blood mononuclear cells (PBMCs) are a new and reliable strategy that can achieve early detection of tumors by identifying marker genes. From 797 datasets, four (GSE12771, GSE24536, GSE27562, and GSE42834) including 428 samples, 236 solid tumor cases, and 192 healthy controls were chosen according to the inclusion criteria. A total of 285 genes from among 440 reported genes were selected by meta-analysis. Among them, 4 of the top significantly differentially expressed genes (ANXA1, IFI44, IFI44L, and OAS1) were identified as marker genes of PBMCs. Pathway enrichment analysis identified, two significant pathways, the ‘primary immunodeficiency’ pathway and the ‘cytokine-cytokine receptor interaction’ pathway. Protein- protein interaction (PPI) network analysis revealed the top 27 hubs with a degree centrality greater than 23 to be hub genes. We also identified 3 modules in Molecular Complex Detection (MCODE) analysis: Cluster 1 (related to ANXA1), Cluster 2 (related to IFI44 and IFI44L) and Cluster 3 (related to OAS1). Among the 4 marker genes, IFI44, IFI44L, and OAS1 are potential diagnostic biomarkers, even though their results were not as remarkable as those for ANXA1 in our study. ANXA1 is involved in the immunosuppressive mechanism in tumor-bearing hosts and may be used in a new strategy involving the use of the host's own immunity to achieve tumor suppression.

由于世界上大多数地区的癌症死亡率都很高，因此早期筛查癌症变得越来越重要。使用外周血单个核细胞（PBMC）的微创筛查程序是一种新的可靠策略，可以通过识别标记基因来实现对肿瘤的早期检测。根据纳入标准，从797个数据集中选择了四个样本（GSE12771，GSE24536，GSE27562和GSE42834），包括428个样本，236个实体瘤病例和192个健康对照。通过荟萃分析从440个报告的基因中总共选择了285个基因。其中，前4个显着差异表达的基因（ANXA1，IFI44，IFI44L和OAS1）被鉴定为PBMC的标记基因。途径富集分析确定了两个重要途径，“原发性免疫缺陷”途径和“细胞因子-细胞因子受体相互作用”途径。蛋白质-蛋白质相互作用（PPI）网络分析显示，中心度大于23的前27个枢纽是枢纽基因。我们还在分子复合物检测（MCODE）分析中确定了3个模块：聚类1（与ANXA1相关），聚类2（与IFI44和IFI44L相关）和聚类3（与OAS1相关）。在4个标记基因中，IFI44，IFI44L和OAS1尽管它们的结果不如我们研究中的ANXA1显着，但它们还是潜在的诊断生物标志物。ANXA1参与荷瘤宿主的免疫抑制机制，并可能用于涉及利用宿主自身免疫力来实现肿瘤抑制的新策略。